Image Place holder

Sophie Dessureault, MD, PhD

Specialty: Surgery
Sub Specialty: General Surgery
Program: Gastrointestinal Oncology


Cancer Focus: Anal Cancer, Colon Cancer, Mesothelioma, Rectal Cancer

Dr. Sophie Dessureault is a surgical oncologist in the Department of Gastrointestinal Oncology at Moffitt Cancer Center.  She is a professor of oncology and surgery at the University of South Florida Morsani College of Medicine.  Dr. Dessureault graduated with distinction from Dalhousie University School of Medicine in Halifax, Nova Scotia.  After medical school, she pursued additional training at the University of Toronto where she completed both a surgical residency and a PhD in the Surgical Scientist Program.  Dr. Dessureault came to Moffitt Cancer Center in 1999 for a fellowship in Surgical Oncology.  She received numerous scholarships and awards, including the Society of Surgical Oncology Young Investigator Award and the American Society of Clinical Oncology Development Award.  In 2008, she was nominated and elected to the Barness-Behnke Chapter of the Gold Humanism Honor Society at the University of South Florida.  She has been nominated for Moffitt Physician of the Year in 2006, 2008, 2009, 2010, and 2016.  Dr. Dessureault is widely published and is a member of numerous professional organizations, including the American Society of Clinical Oncology, Society of Surgical Oncology, Royal College of Surgeons of Canada, and Alpha Omega Alpha Honor Medical Society.  She is fluent in English and French.

Education & Training

Board Certification:

  • Surgery - General Surgery


  • H. Lee Moffitt Cancer Center, University of South Florida - Surgical Oncology


  • University of Toronto, Toronto, Ontario - Surgery

Medical School:

  • Dalhousie University, Halifax, Nova Scotia - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Powers BD, Felder SI, Imanirad I, Dessureault S, Dineen SP. The Impact of Histologic Subtype on Receipt of Adjuvant Chemotherapy and Overall Survival in Stage III Colon Cancer: a Retrospective Cohort Analysis. J Gastrointest Cancer. 2021 Jun.52(2):719-727. Pubmedid: 32743731.
  • Roife D, Powers BD, Zaidi MY, Staley CA, Cloyd JM, Ahmed A, Grotz T, Leiting J, Fournier K, Lee AJ, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Lee B, Blakely A, Greer J, Johnston FM, Laskowitz D, Dessureault S, Dineen SP. CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. Ann Surg Oncol. 2020 Oct.27(13):4996-5004. Pubmedid: 33073341.
  • Yuan Z, Frazer M, Zhang GG, Latifi K, Moros EG, Feygelman V, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Harrison LB, Hoffe SE, Frakes JM. CT-based radiomic features to predict pathological response in rectal cancer: A retrospective cohort study. J Med Imaging Radiat Oncol. 2020 May.64(3):444-449. Pubmedid: 32386109.
  • Beal EW, Ahmed A, Grotz T, Leiting J, Fournier KF, Lee AJ, Dineen S, Dessureault S, Baumgartner JM, Veerapong J, Clarke C, Strong E, Maithel SK, Zaidi MY, Patel S, Dhar V, Hendrix R, Lambert L, Johnston F, Fackche N, Raoof M, LaRocca C, Ronnekleiv-Kelly S, Pokrzywa C, Pawlik TM, Abdel-Misih S, Cloyd JM. Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Am J Surg. 2020 Mar.219(3):478-483. Pubmedid: 31558307.
  • Leiting JL, Cloyd JM, Ahmed A, Fournier K, Lee AJ, Dessureault S, Felder S, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Staley CA, Zaidi MY, Patel SH, Ahmad SA, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Raoof M, LaRocca CJ, Johnston FM, Greer J, Grotz TE. Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative. World J Gastrointest Oncol. 2020 Jul.12(7):756-767. Pubmedid: 32864043. Pmcid: PMC7428797.
  • Powers BD, Felder S, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Staley CA, Maithel SK, Patel S, Dhar V, Lambert L, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Lee B, Johnston FM, Greer J, Cloyd JM, Kimbrough C, Grotz T, Leiting J, Fournier K, Lee AJ, Imanirad I, Dessureault S, Dineen SP. Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study. Ann Surg Oncol. 2020 Apr.27(13):4883-4891. Pubmedid: 32318945.
  • Zaidi MY, Lee RM, Gamboa AC, Speegle S, Cloyd JM, Kimbrough C, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Dessureault S, Kelly KJ, Kotha NV, Clarke C, Gamblin TC, Patel SH, Lee TC, Hendrix RJ, Lambert L, Ronnekleiv-Kelly S, Pokrzywa C, Blakely AM, Lee B, Johnston FM, Fackche N, Russell MC, Maithel SK, Staley CA. Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative. Ann Surg Oncol. 2019 Oct.27(1):156-164. Pubmedid: 31602579. Pmcid: PMC7195626.
  • Kotha NV, Baumgartner JM, Veerapong J, Cloyd JM, Ahmed A, Grotz TE, Leiting JL, Fournier K, Lee AJ, Dineen SP, Dessureault S, Clarke C, Mogal H, Zaidi MY, Russell MC, Patel SH, Sussman JJ, Dhar V, Lambert LA, Hendrix RJ, Abbott DE, Pokrzywa C, Lafaro K, Lee B, Greer JB, Fackche N, Lowy AM, Kelly KJ. Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. Ann Surg Oncol. 2019 Jul.26(7):2234-2240. Pubmedid: 31016486.
  • Sabesan A, Felder S, Feuerlein S, Lam C, McGettigan M, Powers BD, Dessureault S, Dineen SP. Preoperative Radiographic Assessment Predicts Incomplete Cytoreduction in Patients with Low Grade Mucinous Adenocarcinoma of the Appendix. Ann Surg Oncol. 2019 Aug.27(1):165-170. Pubmedid: 31388776.
  • DiSano JA, Wischhusen J, Schaefer EW, Dessureault S, Wong J, Soybel DI, Pameijer CR. Postoperative hyperglycemia in patients undergoing cytoreductive surgery and HIPEC: A cohort study. Int J Surg. 2019 Apr.64:5-9. Pubmedid: 30772524.
  • Koskan AM, Thomas-Purcell KB, Yu D, Quinn GP, Dessureault S, Shibata D, Jacobsen PB, Gwede CK. Discussion of First-Degree Relatives' Colorectal Cancer Risk: Survivors' Perspectives. Health Commun. 2014 Sep.29(8):782-790. Pubmedid: 24229427.
  • Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessureault S. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience. Ann Surg Oncol. 2014 May.21(5):1480-1486. Pubmedid: 24158467.
  • Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, Osada T, Onaitis M, Clary BM, Hsu D, Devi GR, Bulusu A, Annechiarico RP, Chadaram V, Clay TM, Lyerly HK. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg. 2013 Dec.258(6):879-886. Pubmedid: 23657083. Pmcid: PMC3812363.
  • Kiluk JV, Dessureault S, Quinn G. Teaching medical students how to break bad news with standardized patients. J Cancer Educ. 2012 Jun.27(2):277-280. Pubmedid: 22314793. Pmcid: PMC4504018.
  • Kiluk JV, Ly QP, Meade T, Ramos D, Reintgen DS, Dessureault S, Davis M, Shamehdi C, Cox CE. Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up. Ann Surg Oncol. 2011 Dec.18 Suppl 3:S339-S342. Pubmedid: 19777181.
  • Manne S, Jacobsen PB, Ming ME, Winkel G, Dessureault S, Lessin SR. Tailored versus generic interventions for skin cancer risk reduction for family members of melanoma patients. Health Psychol. 2010 Nov.29(6):583-593. Pubmedid: 21090893. Pmcid: PMC3058834.
  • Desai S, Maurin M, Smith MA, Bolick SC, Dessureault S, Tao J, Sotomayor E, Wright KL. PRDM1 is required for mantle cell lymphoma response to bortezomib. Mol Cancer Res. 2010 Jun.8(6):907-918. Pubmedid: 20530581. Pmcid: PMC2891394.
  • Bui MM, Draper NL, Dessureault S, Nasir NA, Cooper H, Nasir A, Coppola D. Colonic angiolymphoid hyperplasia with eosinophilia masquerading as malignancy: a case report and review of the literature. Clin Colorectal Cancer. 2010 Jul.9(3):179-182. Pubmedid: 20643624.
  • Kiluk JV, Ly QP, Santillan AA, Meade T, Ramos D, Reintgen DS, Dessureault S, Davis M, Shamehdi C, Cox CE. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up. Ann Surg Oncol. 2010 Feb.17(2):552-557. Pubmedid: 19957043.
  • Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, Sotomayor E, Tao J, Cheng JQ. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 2010 Apr.115(13):2630-2639. Pubmedid: 20086245. Pmcid: PMC2852365.
  • Giglia JL, Antonia SJ, Berk LB, Bruno S, Dessureault S, Finkelstein SE. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Cancer Control. 2010 Apr.17(2):120-129. Pubmedid: 20404795.
  • Lwin T, Crespo LA, Wu A, Dessureault S, Shu HB, Moscinski LC, Sotomayor E, Dalton WS, Tao J. Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis. Leukemia. 2009 Jan.23(1):170-177. Pubmedid: 18843286.
  • Moller M, Lewis J, Dessureault S, Zager J. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia. 2008 May.24(3):275-289. Pubmedid: 18393005.
  • Lewis J, Zager J, Yu D, Pelaez D, Riker A, Dessureault S, Cruse C, Reintgen D, Puleo C, Sondak V. Full-thickness grafts procured from skin overlying the sentinel lymph node basin; reconstruction of primary cutaneous malignancy excision defects. Ann Surg Oncol. 2008 Jun.15(6):1733-1740. Pubmedid: 18379848.
  • Dessureault S. Ongoing Studies with GM. Cd40L Bystander-Based Vaccines. 2008 Jan.15(4):1255.
  • Lwin T, Hazlehurst LA, Dessureault S, Lai R, Bai W, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood. 2007 Sep.110(5):1631-1638. Pubmedid: 17502456. Pmcid: PMC1975846.
  • Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia. 2007 Jul.21(7):1521-1531. Pubmedid: 17476277.
  • Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A, Sotomayor E, Messina J, Antonia S. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann Surg Oncol. 2007 Feb.14(2):869-884. Pubmedid: 17103257.
  • Thompson P, Dessureault S. Tumor cell vaccines. Adv Exp Med Biol. 2007.601:345-355. Pubmedid: 17713023.
  • Dessureault S. Commentary: Evidence-based principles applied to the management of colorectal cancer. Cancer Treat Rev. 2006 Nov.32(7):581. Pubmedid: 16884857.
  • Cox C, White L, Allred N, Meyers M, Dickson D, Dupont E, Cantor A, Ly Q, Dessureault S, King J, Nicosia S, Vrcel V, Diaz N. Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy. Ann Surg Oncol. 2006 May.13(5):708-711. Pubmedid: 16538416.
  • Azzarello L, Dessureault S, Jacobsen P. Sun-protective behavior among individuals with a family history of melanoma. Cancer Epidemiol Biomarkers Prev. 2006 Jan.15(1):142-145. Pubmedid: 16434600.
  • Dessureault S, Alsarraj M, McCarthy S, Hunter T, Noyes D, Lee D, Harkins J, Seigne J, Jennings R, Antonia S. A GM-CSF/CD40L producing cell augments anti-tumor T cell responses. J Surg Res. 2005 May.125(2):173-181. Pubmedid: 15854671.
  • Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 2002 Sep.101(2):151-155. Pubmedid: 12209992.
  • Kim C, Dessureault S, Gabrilovich D, Reintgen D, Slingluff C. Immunotherapy for melanoma. Cancer Control. 2002 Jan.9(1):22-30. Pubmedid: 11907463.
  • Dessureault S, Coppola D, Weitzner M, Powers P, Karl R. Barrett's esophagus and squamous cell carcinoma in a patient with psychogenic vomiting. Int J Gastrointest Cancer. 2002.32(1):57-61. Pubmedid: 12630772.
  • Dessureault S, Soong S, Ross M, Thompson J, Kirkwood J, Gershenwald J, Coit D, McMasters K, Balch C, Reintgen D. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001 Dec.8(10):766-770. Pubmedid: 11776489.
  • Dessureault S, Graham F, Gallinger S. Autologous lymphocyte responses to adenovirus-B7-1-transduced human cancer cells. Cancer Gene Ther. 1999 May.6(3):195-208. Pubmedid: 10359205.
  • Stewart A, Lassam N, Quirt I, Bailey D, Rotstein L, Krajden M, Dessureault S, Gallinger S, Cappe D, Wan Y, Addison C, Moen R, Gauldie J, Graham F. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther. 1999 Mar.6(3):350-363. Pubmedid: 10435085.
  • Prince H, Dessureault S, Gallinger S, Krajden M, Sutherland D, Addison C, Zhang Y, Graham F, Stewart S. Efficient adenovirus-mediated gene expression in malignant human plasma cells: relative lymphoid cell resistance. Exp Hematol. 1998 Jan.26(1):27-36. Pubmedid: 9430511.
  • Dessureault S, Shpitz B, Alloo J, Rotstein O, Sandhu J, Hozumi N, Fernandes B, Gallinger S. Physiologic human T-cell responses to OKT3 in the human peripheral blood lymphocyte-severe combined immunodeficiency mouse model. Transplantation. 1997 Sep.64(6):811-816. Pubmedid: 9326403.
  • Stewart AK, Lassam NJ, Graham FL, Gauldie J, Addison CL, Bailey DJ, Dessureault S, Dubé ID, Gallenger S, Krajden M, Rotstein LE, Quirt IC, Moen R. A phase I study of adenovirus mediated gene transfer of interleukin 2 cDNA into metastatic breast cancer or melanoma. Hum Gene Ther. 1997 Jul.8(11):1403-1414. Pubmedid: 9295135.
  • Dessureault S, Koven I, Reilly RM, Couture J, Schmocker B, Damani M, Kirsh J, Ichise M, Sidlofsky S, McEwan AJ, Boniface G, Stern H, Gallinger S. Pre-operative assessment of axillary lymph node status in patients with breast adenocarcinoma using intravenous 99mtechnetium mAb-170H.82 (Tru-Scint AD). Breast Cancer Res Treat. 1997 Aug.45(1):29-37. Pubmedid: 9285114.
  • Dessureault S, Graham F, Gallinger S. B7-1 gene transfer into human cancer cells by infection with an adenovirus-B7 (Ad-B7) expression vector. Ann Surg Oncol. 1996 May.3(3):317-324. Pubmedid: 8726189.
  • Dessureault S, Gallinger S. Allogeneic lymphocyte responses to B7-1 expressing human cancer cell lines. J Surg Res. 1996 Jul.64(1):42-48. Pubmedid: 8806472.
  • Dessureault S, Brown P, Ghose T, Kamra OP, Belitsky P. Sensitivity of normal and neoplastic human renal tubular epithelium to hyperthermia. Cancer Lett. 1988 Dec.43(1-2):1-8. Pubmedid: 3203319.

Patient Comments
Overall Satisfaction

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments